Tierney et al. [41] found the low PD-L1 and strong PD-L2 expression in ACC tumors and stromal tissues than in ACAs, suggesting that PD-L2 could be a target for immunotherapy. This evidence concerns the gene PDCD1LG2 and adrenal cortex carcinoma.